For the Quarter Ending December 2025
Gabapentin Prices in North America
- In United States, the Gabapentin Price Index rose quarter-over-quarter in Q4 2025, driven by increased production costs and robust demand.
- Gabapentin production costs increased as CPI rose 2.7% year-over-year in December 2025, impacting raw materials and labor.
- Producer Price Index increased 3.0% year-over-year in November 2025, raising input costs for Gabapentin manufacturers.
- Strong Gabapentin demand in Q4 2025 was supported by surging US drug spending and renewed healthcare sector interest.
- Retail sales increased 3.3% year-over-year in November 2025, bolstering overall healthcare spending and patient affordability.
- A 4.4% unemployment rate in December 2025 bolstered patient access and affordability for prescription medications like Gabapentin.
- Energy costs for Gabapentin manufacturing increased as natural gas CPI surged year-over-year through October 2025.
- Industrial production increased 2.0% year-over-year in December 2025, supporting stable supply of general chemical inputs.
Why did the price of Gabapentin change in December 2025 in North America?
- Production costs rose from 2.7% CPI in December 2025 and 3.0% PPI in November 2025.
- Strong drug demand in Q4 2025 was supported by 3.3% retail sales growth in November 2025.
- Higher energy costs, including surging natural gas CPI through October 2025, increased manufacturing expenses.
Gabapentin Prices in APAC
- In China, the Gabapentin Price Index fell in Q4 2025, influenced by weak consumer demand and declining production costs.
- Gabapentin production costs declined in Q4 2025, driven by a 1.9% PPI contraction and benzene feedstock cost downturn.
- Gabapentin demand outlook remained supported by an aging population and chronic illnesses in China during 2025.
- China's Consumer Price Index (CPI) rose only 0.8% year-on-year in December 2025, reflecting weak consumer demand.
- Petrochemical markets in China experienced an oversupply in November 2025, contributing to inventory overhangs.
- China's Manufacturing Index expanded in December 2025, supporting the overall supply chain for intermediates.
- Industrial Production increased by 5.2% year-on-year in December 2025, indicating a robust manufacturing sector.
- Gabapentin price forecast suggests continued pressure from mounting aromatics supply overhangs in Q4 2025.
Why did the price of Gabapentin change in December 2025 in APAC?
- Weak consumer demand, with CPI up 0.8% year-on-year in December 2025, limited pricing power.
- Production costs declined due to a 1.9% PPI contraction and benzene feedstock cost downturn in Q4 2025.
- Oversupply in petrochemical markets and increased chemical capacity intensified competition during Q4 2025.
Gabapentin Prices in Europe
- In Germany, the Gabapentin Price Index fell quarter-over-quarter in Q4 2025, influenced by a 2.5% decline in producer prices in December 2025.
- Gabapentin production costs faced downward pressure from bearish benzene feedstock prices anticipated for Q4 2025.
- The Gabapentin demand outlook was dampened by a contracting Manufacturing Index in December 2025 and weak general chemical demand.
- Operational costs for Gabapentin manufacturers increased due to a 1.8% rise in the Consumer Price Index in December 2025.
- Germany's economic activity saw a slight uptick in Q4 2025, yet consumer confidence remained negative at -17.5 in December 2025.
- Industrial production grew 0.8% in October 2025, and retail sales increased 1.1% in November 2025.
- The unemployment rate was 6.2% in December 2025, indicating a moderately stable labor market.
- Low capacity utilization in the German chemical sector throughout Q4 2025 suggested efforts to reduce inventories.
Why did the price of Gabapentin change in December 2025 in Europe?
- Producer prices declined 2.5% in December 2025, reducing Gabapentin input costs in Germany.
- Bearish benzene feedstock prices in Q4 2025 lowered Gabapentin production costs in Germany.
- Contracting manufacturing activity and negative consumer confidence (-17.5) dampened demand in Germany in December 2025.
For the Quarter Ending September 2025
North America
- In the United States, the Gabapentin Price Index fell quarter-over-quarter in Q3 2025, influenced by softened cyclohexanone feedstock prices.
- Gabapentin production costs eased in Q3 2025 due to falling cyclohexanone feedstock prices, relieving cost-push inflation.
- Overall US health spending is projected to reach $5.6 trillion in 2025, supporting pharmaceutical demand.
- FDA safety labeling changes for opioids, including gabapentinoid warnings, influenced Gabapentin demand.
- Macroeconomic indicators showed CPI at 3.0% (September 2025) and PPI at 2.6% (August 2025), reflecting inflationary pressures.
- Industrial production rose 0.1% (September 2025), retail sales increased 5.0% (August 2025), indicating economic activity.
- Unemployment was 4.3% (August 2025), with consumer confidence at 96.67 (September 2025), suggesting stable labor and sentiment.
- US natural gas prices rose 32.1% year-over-year in September 2025, increasing energy-intensive production costs.
Why did the price of Gabapentin change in September 2025 in North America?
- Cyclohexanone feedstock prices softened in Q3 2025, directly easing Gabapentin production costs.
- FDA policy changes regarding gabapentinoids influenced Gabapentin demand in the US.
- Rising US natural gas prices in September 2025 increased energy inputs, partially offsetting feedstock relief.
APAC
- In China, the Gabapentin Price Index fell quarter-over-quarter, influenced by contracting producer prices in September 2025.
- Gabapentin production costs decreased in Q3 2025, driven by a 6.1% decline in Cyclohexanone feedstock prices.
- High Cyclohexanone inventories in Q3 2025, due to weak downstream demand, contributed to lower input costs.
- Gabapentin demand outlook remains positive, supported by China's expanding pharmaceutical market and aging population.
- China's Manufacturing Index was contracting in September 2025, indicating a slowdown in overall industrial activity.
- Consumer Price Index (CPI) contracted by 0.3% year-on-year in September 2025, reflecting broader deflationary pressures.
- Retail sales expanded by 3.0% year-on-year in September 2025, suggesting some consumer spending resilience.
- Policy changes, including NRDL updates and streamlined drug registration, support the innovative drug segment's growth.
Why did the price of Gabapentin change in September 2025 in APAC?
- Gabapentin production costs decreased due to a 6.1% decline in Cyclohexanone feedstock prices during Q3 2025.
- High Cyclohexanone inventories in Q3 2025, stemming from weak downstream demand, exerted downward price pressure.
- The Producer Price Index (PPI) contracted by 2.3% year-on-year in September 2025, reflecting broader market deflation.
Europe
- In Germany, the Gabapentin Price Index fell quarter-over-quarter in Q3 2025, due to contracting industrial production and cost containment.
- Gabapentin production costs trended lower in Q3 2025, with producer prices decreasing 1.7% year-on-year in September.
- Gabapentin demand was supported by Germany's pharmaceutical market, with retail sales increasing 0.2% year-on-year.
- The Gabapentin Price Index faced downward pressure from an extended price moratorium freezing prices until 2026.
- German pharmaceutical production volume dropped 0.3% in Q3 2025, 1.5% lower than one year earlier.
- Euro Area chemical imports were EUR 29758.70 million in August 2025; container freight rates fell for eleven weeks.
- Policy changes, including the EU 'pharma package' and German cost containment, are reshaping the pharmaceutical market.
- Consumer Price Index increased to 2.4% year-on-year in September, reflecting low consumer sentiment at -23.5 index points.
- The Manufacturing Index was contracting in Q3 2025, as industrial production decreased 1.0% and unemployment rose to 3.9%.
Why did the price of Gabapentin change in September 2025 in Europe?
- Producer prices decreased 1.7% year-on-year in September 2025, reducing Gabapentin input costs.
- Contracting Manufacturing Index and 1.0% year-on-year industrial production drop dampened demand.
- Germany's upheld pharmaceutical cost containment measures, including discounts, exerted downward pressure.
